Immune checkpoints are predominantly co-expressed by clonally expanded CD4⁺FoxP3⁺ intratumoral T-cells in primary human cancers.

ABSTRACT:

Background

In addition to anti-PD(L)1, anti-CTLA-4 and anti-LAG-3, novel immune checkpoint proteins (ICP)-targeted antibodies have recently failed to demonstrate significant efficacy in clinical trials. In these trials, patients were enrolled without screening for drug target expression. Although these novel ICP-targeted antibodies were expected to stimulate anti-tumor CD8 + T-cells, the rationale for their target expression in human tumors relied on pre-clinical IHC stainings and transcriptomic data, which are poorly sensitive and specific techniques for assessing membrane protein expression on immune cell subsets. Our aim was to describe ICP expression on intratumoral T-cells from primary solid tumors to better design upcoming neoadjuvant cancer immunotherapy trials.

Methods</

SUBMITTER: Bredel D 

PROVIDER: S-EPMC10699039 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature